🚀 VC round data is live in beta, check it out!
Imugene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Imugene and similar public comparables like Generation Bio, Outlook Therapeutics, FibroGen, Mabion and more.
Imugene Overview
About Imugene
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Founded
1986
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$30M
Imugene Financials
Imugene reported last 12-month revenue of $3M and negative EBITDA of ($44M).
In the same LTM period, Imugene generated ($44M) in EBITDA losses and had net loss of ($45M).
Revenue (LTM)
Imugene P&L
In the most recent fiscal year, Imugene reported revenue of — and net income of —.
Imugene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($44M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (1525%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (1748%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (1569%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Imugene Stock Performance
Imugene has current market cap of $36M, and enterprise value of $30M.
Market Cap Evolution
Imugene's stock price is $0.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $36M | -32.2% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImugene Valuation Multiples
Imugene trades at 10.4x EV/Revenue multiple, and (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Imugene Financial Valuation Multiples
As of April 8, 2026, Imugene has market cap of $36M and EV of $30M.
Equity research analysts estimate Imugene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Imugene has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV/Revenue | 10.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (0.7x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (0.6x) | XXX | — | XXX | XXX | XXX |
| P/E | (0.8x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (0.6x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Imugene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Imugene Margins & Growth Rates
Imugene's revenue in the last fiscal year grew by 0%.
Imugene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | (1525%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (25%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | 768% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1061% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Imugene Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Generation Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| FibroGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imugene M&A Activity
Imugene acquired XXX companies to date.
Last acquisition by Imugene was on XXXXXXXX, XXXXX. Imugene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Imugene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImugene Investment Activity
Imugene invested in XXX companies to date.
Imugene made its latest investment on XXXXXXXX, XXXXX. Imugene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Imugene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Imugene
| When was Imugene founded? | Imugene was founded in 1986. |
| Where is Imugene headquartered? | Imugene is headquartered in Australia. |
| How many employees does Imugene have? | As of today, Imugene has over 23 employees. |
| Who is the CEO of Imugene? | Imugene's CEO is Leslie Chong. |
| Is Imugene publicly listed? | Yes, Imugene is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Imugene? | Imugene trades under IMU ticker. |
| When did Imugene go public? | Imugene went public in 1993. |
| Who are competitors of Imugene? | Imugene main competitors are Generation Bio, Outlook Therapeutics, FibroGen, Mabion. |
| What is the current market cap of Imugene? | Imugene's current market cap is $36M. |
| What is the current revenue of Imugene? | Imugene's last 12 months revenue is $3M. |
| What is the current EV/Revenue multiple of Imugene? | Current revenue multiple of Imugene is 10.4x. |
| Is Imugene profitable? | No, Imugene is not profitable. |
| What is the current EBITDA of Imugene? | Imugene has negative EBITDA and is not profitable. |
| What is Imugene's EBITDA margin? | Imugene's last 12 months EBITDA margin is (1525%). |
| What is the current EV/EBITDA multiple of Imugene? | Current EBITDA multiple of Imugene is (0.7x). |
| What is the current FCF of Imugene? | Imugene's last 12 months FCF is ($48M). |
| What is Imugene's FCF margin? | Imugene's last 12 months FCF margin is (1675%). |
| What is the current EV/FCF multiple of Imugene? | Current FCF multiple of Imugene is (0.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.